[go: up one dir, main page]

GT200100238AA - Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis (solicitud fraccionaria # 1 derivada de lapi-2001-0238) - Google Patents

Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis (solicitud fraccionaria # 1 derivada de lapi-2001-0238)

Info

Publication number
GT200100238AA
GT200100238AA GT200100238AK GT200100238K GT200100238AA GT 200100238A A GT200100238A A GT 200100238AA GT 200100238A K GT200100238A K GT 200100238AK GT 200100238 K GT200100238 K GT 200100238K GT 200100238A A GT200100238A A GT 200100238AA
Authority
GT
Guatemala
Prior art keywords
osteoporosis
fractionary
lapi
receptor
derived
Prior art date
Application number
GT200100238AK
Other languages
English (en)
Spanish (es)
Inventor
Kimberly O'keefe Cameron
Bruce Allen Lefker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100238AA publication Critical patent/GT200100238AA/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT200100238AK 2000-11-27 2001-11-27 Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis (solicitud fraccionaria # 1 derivada de lapi-2001-0238) GT200100238AA (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27

Publications (1)

Publication Number Publication Date
GT200100238AA true GT200100238AA (es) 2004-05-12

Family

ID=22959588

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200100238AK GT200100238AA (es) 2000-11-27 2001-11-27 Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis (solicitud fraccionaria # 1 derivada de lapi-2001-0238)
GT200100238A GT200100238A (es) 2000-11-27 2001-11-27 Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
GT200100238A GT200100238A (es) 2000-11-27 2001-11-27 Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.

Country Status (41)

Country Link
US (3) US6552067B2 (et)
EP (1) EP1339678B1 (et)
JP (2) JP3984164B2 (et)
KR (1) KR20030053063A (et)
CN (1) CN1476429A (et)
AR (1) AR035074A1 (et)
AT (1) ATE374182T1 (et)
AU (1) AU2002210848A1 (et)
BG (1) BG107697A (et)
BR (1) BR0115687A (et)
CA (1) CA2429850C (et)
CY (1) CY1106976T1 (et)
CZ (1) CZ20031257A3 (et)
DE (1) DE60130675T2 (et)
DK (1) DK1339678T3 (et)
EA (1) EA200300379A1 (et)
EC (1) ECSP034623A (et)
EE (1) EE200300246A (et)
ES (1) ES2291361T3 (et)
GT (2) GT200100238AA (et)
HN (1) HN2001000266A (et)
HU (1) HUP0400807A2 (et)
IL (1) IL155368A0 (et)
IS (1) IS6775A (et)
MA (1) MA26961A1 (et)
MX (1) MXPA03004623A (et)
NO (1) NO20032360L (et)
NZ (1) NZ525164A (et)
OA (1) OA12533A (et)
PA (1) PA8533901A1 (et)
PE (1) PE20020637A1 (et)
PL (1) PL362030A1 (et)
PT (1) PT1339678E (et)
SI (1) SI1339678T1 (et)
SK (1) SK5562003A3 (et)
SV (1) SV2003000746A (et)
TN (1) TNSN01166A1 (et)
TW (1) TW200424170A (et)
UY (1) UY27038A1 (et)
WO (1) WO2002042268A2 (et)
ZA (1) ZA200302803B (et)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525164A (en) * 2000-11-27 2005-04-29 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
AU2002328855B2 (en) * 2001-07-16 2005-11-24 F. Hoffmann-La Roche Ag Prostaglandin Analogues As EP4 Receptor Agonists
PT1408961E (pt) * 2001-07-16 2007-10-10 Ono Pharmaceutical Co Derivados de 2-pirrolidona como agonistas de prostanóides
KR100826866B1 (ko) * 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
CA2477715A1 (en) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
CA2478653A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
EP1513589B1 (en) * 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
US20060258726A1 (en) * 2002-06-06 2006-11-16 Xavier Billot 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
AU2003237520B2 (en) * 2002-06-10 2009-01-08 Laboratoires Serono Sa Gamma lactams as prostaglandin agonists and use thereof
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
ES2393321T3 (es) 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
WO2004043354A2 (en) 2002-11-08 2004-05-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
PL378342A1 (pl) * 2003-01-10 2006-03-20 F. Hoffmann-La Roche Ag Pochodne 2-piperydonu jako agoniści prostaglandyn
EP1586564B1 (en) * 2003-01-21 2012-11-28 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medicinal uses thereof
EP1603874B1 (en) 2003-03-03 2008-05-07 Laboratoires Serono SA G-lactam derivatives as prostaglandin agonists
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US7465755B2 (en) 2003-07-18 2008-12-16 Laboratoires Serono Sa Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
AU2004268012B2 (en) 2003-09-02 2008-11-20 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
AU2004272546B2 (en) 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
JP2007504236A (ja) 2003-09-04 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼用組成物
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
MXPA06006810A (es) * 2003-12-17 2006-08-23 Pfizer Prod Inc Tratamiento de afecciones que se presentan con un nivel bajo de masa osea por terapia de combinacion continua con agonistas selectivos del receptor de prostaglandina ep4 y un estrogeno.
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
CN1988903A (zh) 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
CA2585367A1 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7994195B2 (en) * 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
US7547685B2 (en) * 2004-11-08 2009-06-16 Allergan, Inc. Therapeutic substituted pyrrolidone compounds
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
WO2006080323A1 (ja) * 2005-01-27 2006-08-03 Asahi Kasei Pharma Corporation ヘテロ６員環化合物及びその用途
US8420628B2 (en) * 2005-05-06 2013-04-16 Allergan, Inc. Substituted beta-lactams
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
US20100081631A1 (en) * 2006-12-18 2010-04-01 Guang Liang Jiang Methods and compositions for treating gastrointenstial disorders
MX2009012043A (es) 2007-05-08 2010-02-18 Nat Univ Corp Hamamatsu Activador de celulas t citotoxicas que comprende agonista ep4.
DK2155733T3 (da) * 2007-05-23 2012-10-29 Allergan Inc Cykliske lactamer til behandling af glaukom eller forhøjet intraokulært tryk
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
US8404736B2 (en) * 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
US20120190637A1 (en) 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
CN102917703B (zh) * 2010-03-08 2015-08-19 科研制药株式会社 新型ep4激动剂
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (en) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Process for the synthesis of beta-amino acids and derivatives thereof
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
CA2827615A1 (en) 2011-02-17 2012-08-23 Dennis E. Van Epps Compositions and improved soft tissue replacement methods
WO2013105997A2 (en) 2011-02-23 2013-07-18 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814482A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (en) 2012-02-16 2016-11-02 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814510A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814527A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
CA2879507A1 (en) 2012-07-19 2014-01-23 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CA2903314C (en) 2013-03-15 2023-02-14 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
DK2989098T3 (en) * 2013-03-15 2017-08-28 Cayman Chemical Co Inc LACTAM RELATIONS AS EP4 RECEPTOR SELECTIVE AGONISTS FOR USING THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
WO2015009991A2 (en) * 2013-07-19 2015-01-22 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
WO2015056504A1 (ja) 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
RU2016150902A (ru) 2014-06-06 2018-07-17 Аллерган, Инк. Новые агонисты ep4 в качестве терапевтических соединений
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
KR102387896B1 (ko) * 2016-03-04 2022-04-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 프로스타글란딘 e2를 이용한 근육 재생을 위한 조성물 및 방법
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
AU2018396402C1 (en) 2017-12-25 2021-03-18 Asahi Kasei Pharma Corporation Nitrogen-containing 6-membered cyclic compound
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
SE423813B (sv) * 1976-08-06 1982-06-07 Pfizer Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4320136A (en) * 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (et) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
TW420669B (en) 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
AU1444200A (en) 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for inhibiting bone resorption
GEP20043203B (en) * 1999-12-22 2004-03-25 Pfizer Prod Inc EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
IL141120A0 (en) * 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
NZ525164A (en) * 2000-11-27 2005-04-29 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
BG107697A (en) 2004-01-30
JP3984164B2 (ja) 2007-10-03
US20040259921A1 (en) 2004-12-23
US6552067B2 (en) 2003-04-22
AU2002210848A1 (en) 2002-06-03
ATE374182T1 (de) 2007-10-15
ZA200302803B (en) 2004-04-13
EP1339678A2 (en) 2003-09-03
WO2002042268A3 (en) 2002-07-25
EP1339678B1 (en) 2007-09-26
MA26961A1 (fr) 2004-12-20
MXPA03004623A (es) 2003-09-05
AR035074A1 (es) 2004-04-14
PT1339678E (pt) 2007-11-30
CA2429850C (en) 2008-12-30
ES2291361T3 (es) 2008-03-01
CZ20031257A3 (cs) 2004-04-14
GT200100238A (es) 2002-06-26
PL362030A1 (en) 2004-10-18
OA12533A (en) 2006-06-05
ECSP034623A (es) 2003-07-25
US20030149086A1 (en) 2003-08-07
US20020065308A1 (en) 2002-05-30
PE20020637A1 (es) 2002-07-18
CY1106976T1 (el) 2012-09-26
DK1339678T3 (da) 2008-02-04
PA8533901A1 (es) 2002-11-28
NO20032360D0 (no) 2003-05-26
EE200300246A (et) 2003-10-15
HN2001000266A (es) 2002-01-30
IS6775A (is) 2003-04-10
CN1476429A (zh) 2004-02-18
HUP0400807A2 (hu) 2004-07-28
DE60130675D1 (de) 2007-11-08
DE60130675T2 (de) 2008-01-24
US6747054B2 (en) 2004-06-08
IL155368A0 (en) 2003-11-23
TW200424170A (en) 2004-11-16
WO2002042268A2 (en) 2002-05-30
NO20032360L (no) 2003-07-23
SV2003000746A (es) 2003-01-13
SI1339678T1 (sl) 2007-12-31
BR0115687A (pt) 2003-09-09
US7192979B2 (en) 2007-03-20
CA2429850A1 (en) 2002-05-30
NZ525164A (en) 2005-04-29
EA200300379A1 (ru) 2003-08-28
SK5562003A3 (en) 2004-08-03
JP2004521869A (ja) 2004-07-22
JP2007197467A (ja) 2007-08-09
KR20030053063A (ko) 2003-06-27
UY27038A1 (es) 2002-07-31
TNSN01166A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
GT200100238AA (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis (solicitud fraccionaria # 1 derivada de lapi-2001-0238)
CR6678A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
BR0308208A (pt) Composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, métodos para inibir a atividade de catepsina em um mamìfero que disto necessita, para tratar ou prevenir uma doença, para tratar condições dependentes de catepsina em um mamìfero que disto necessita, para inibir ressorção óssea, para incrementar a densidade mineral óssea, e, para reduzir o risco de fraturas
BR0211364A (pt) Composição farmacêutica para tratamento de doenças associadas com redução na massa óssea compreendendo o agonista ep4 como componente ativo
BR0100381A (pt) Tratamento de osteoporose com agonistasseletivos do receptor ep/2/ep4
BR0111210A (pt) Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias
AR060409A1 (es) Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja y la terapia combinada relacionada a estos agonistas
BRPI0513491A (pt) composições inseticidas com base em inseticidas e saffeners selecionados
PA8452701A1 (es) Agonistas de prostaglandinas
BR0310087A (pt) Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas
BR0203388A (pt) Composição endoparasiticida em gel
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
DE60225143D1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
AU2003251728A8 (en) Placental growth factor as a target for the treatment of osteoporosis
CR6952A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis
GB0422929D0 (en) Bioactive vitamin D analogues
IL156639A0 (en) Phenethanolamine derivatives, methods for their preparation and pharmaceutical compositions containing them
ECSP972347A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
GT199800084A (es) Derivados dipeptidicos.
UY26651A1 (es) Terapia combinada para la osteoporosis
ECSP982554A (es) Agonistas de prostaglandinas